


Indian Immunologicals focus on infrastructure expansion

09 June 2009 | News



Indian Immunologicals focus on infrastructure expansion

Indian Immunologicals with a range of flagship products in the animal health market has become the largest animal health brand in India.



The National Dairy Development Board (NDDB) sets up Indian Immunologicals Ltd (IIL) in 1982 with the objective of making foot and mouth disease (FMD) vaccine available to farmers at an affordable price. Subsequently, IIL has developed many biologicals through its own R&D efforts and launched several vaccines in the Indian market at affordable prices. IIL is today a market leader in veterinary biologicals in India. It operates one of the largest plants in the world for veterinary vaccines and is WHO-GMP and ISO-9001 certified. IIL exports its products to substantially to the company's turnover.

IIL is the largest player in veterinary vaccine market in India with a depth in marketing throughout the country, reaching out to the smallest of livestock keepers. Many of its products enjoy strong patronage from veterinarians and as a result, occupy the top slots in market share. IIL has a range of vaccines for cattle, sheep and canine segments, combined with its presence in the formulations e Indian animal health market.

IIL posted a biotech sales turnover of Rs 231.46 crore for the fiscal year ended March 2009 as against Rs 196 crore in 2007-08. The company expects to cross the Rs 300 crore revenue mark by 2010. IIL currently employs 1,187 people and plans to hire another 150 in the coming year. The company has invested more than Rs 30 lakh in 2008 and plans to triple this amount by next year, mainly in R&D

IIL's flagship product in the animal health market is its Raksha FMD vaccine, which is the largest animal health brand in India. IIL meets more than 80 percent of the requirement of the vaccine in India. With a large repository of various FMD virus strains maintained in the laboratory, IIL is able to provide FMD vaccines of customer's choice and as per epidemiological requirement for other countries. IIL ine to FAO.

IIL is also a major player in the human vaccine market in India, especially in the pediatric vaccine and the rabies product segments. In the human vaccine market, IIL holds the fourth position. IIL exports its products to several countries and exports contribute substantially to the company's turnover. Future Plans: The company has acquired 50 acre of land in Biotech Park – Phase III near Karkapatla to locate its new manufacturing facilities for animal vaccines, health formulations and human vaccines. These facilities will be ready for commercial production by mid 2011.